Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
February 22, 2022 16:05 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
January 19, 2022 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
January 06, 2022 16:05 ET
|
Recro Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro to Present at Stephens Annual Investment Conference
December 02, 2021 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Reports Third Quarter 2021 Financial Results
November 09, 2021 16:05 ET
|
Recro Pharma, Inc.
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of...
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
October 27, 2021 07:00 ET
|
Recro Pharma, Inc.
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN...
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
October 20, 2021 07:00 ET
|
Recro Pharma, Inc.
GAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
October 06, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Penn. and SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Signs Renewable Energy Agreement With Georgia Power
September 21, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 08, 2021 07:00 ET
|
Recro Pharma, Inc.; BioCorRx, Inc.
SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...